Navigation Links
Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
Date:6/29/2010

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure(R), is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology licensed from Mayo Clinic, C-Cure is designed to reprogram the patient's own stem cells into new heart cells to rebuild the heart.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.

Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

About C-Cure and Heart Failure

Heart failure is a serious and common condition in which the heart cannot pump enough blood through the body, leaving the patient debilitated and unable to conduct a normal life. It can result from heart attacks or a number of other causes. Patients suffering from the condition can experience shortness of breath and extreme exhaustion. It affects 28 million patients worldwide and this number is predicted to double by 2020. Therapies available for chronic heart failure aim at slowing down the disease progression, but with the exception of heart transplant, existing drugs or devices do not cure chronic heart failure.

C-Cure is produced by taking a patient's own stem cells and, through a proprietary process, differentiating them into cardiopoietic cells that can regenerate
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
(Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... LASIK Surgeons directory service and information resource for ... Trusted LASIK Surgeons directory apart is a unique ... surgeon who are among the best in the ... LASIK Surgeon Dr. Parag A. Majmudar, are screened ...
... line in the United ... States and Canada, ... into a partnership that will allow Roche to market,the first line ... the RAMP(R) 200 (Rapid Analyte Measurement Platform), is,based on RAMP technology ...
... Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading provider ... reflux disease, today,announced its plans to present at the ... held August 5-6, 2008, at the Millennium,Broadway Hotel in ... for 10:00 a.m. ET on,Wednesday, August 6, and will ...
Cached Biology Technology:Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 2Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 3Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 4Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 5Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 6Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 2Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 3
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has ... - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally different ... the first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Northwest is the focus of two federal grants totaling ... They will work together on a pair of multi-site ... and property from wildfires in the face of a ... the UO,s Center for Ecology and Evolutionary Biology, will ...
... of the element boron in a new generation of drugs ... Boron has to date far been one of biology,s best ... and investment from the pharmaceutical industry in the quest for ... limitations and side effects of current products. Europe,s ...
... Conventional wisdom has been that respiratory syncytial virus (RSV) ... comes and goes in children without any long lasting impact. ... Southwestern Medical Center researchers, however, suggests that RSV may hide ... to cause recurrent wheezing and chronic airway disease. ...
Cached Biology News:Northwest climate change is target of $3.2M in grants to University of Oregon 2Northwest climate change is target of $3.2M in grants to University of Oregon 3Northwest climate change is target of $3.2M in grants to University of Oregon 4European researchers harness unique properties of boron to develop new drugs and diagnostics 2European researchers harness unique properties of boron to develop new drugs and diagnostics 3RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report 2RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report 3
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
Carrier Serum...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
... Taq is a derivative of Taq DNA ... Thermus aquaticus DNA polymerase. Expressed from a ... at Met236, bypassing the 5'-3' exonuclease domain ... reveals a highly active and even more ...
Biology Products: